Inequities in Time to Treat Thyroid Cancer.

Autor: Kowkabany G; University of Alabama, Tuscaloosa, AL, U.S.A.; gakowkabany@crimson.ua.edu., Jimenez PB; University of Puerto Rico, San Juan, Puerto Rico., Sharan S; Government Medical College, Chandigarh, India., Bansal S; Government Medical College, Chandigarh, India., Ahmed SH; Dow University of Health Sciences, Karachi, Pakistan., Raikot S; Mayo Clinic, Rochester, MN, U.S.A., Manaise HK; Government Medical College and Hospital, Chandigarh, India., Popp R; University of Florida College of Medicine, Gainesville, FL, U.S.A., Popp K; Florida State University, Tallahassee, FL, U.S.A., Sukniam KB; Duke University Medical Center, Durham, NC, U.S.A., Gabriel E; Department of General Surgery, Division of Surgical Oncology, Mayo Clinic Florida, Jacksonville, FL, U.S.A.
Jazyk: angličtina
Zdroj: Anticancer research [Anticancer Res] 2023 Nov; Vol. 43 (11), pp. 5025-5030.
DOI: 10.21873/anticanres.16701
Abstrakt: Background/aim: The purpose of this study was to determine socioeconomic and demographic factors which may contribute to inequities in time to treat thyroid cancer.
Patients and Methods: We used data from the National Cancer Database, 2004-2019, to conduct an analysis of thyroid cancer patients. All (434,083) patients with thyroid cancer, including papillary (395,598), follicular (23,494), medullary (7,638), and anaplastic (7,353) types were included. We compared the wait time from diagnosis to first treatment, surgery, radiotherapy, and chemotherapy for patients based on age, race, sex, location, and socioeconomic status (SES).
Results: A total of 434,083 patients with thyroid cancer were included. Hispanic patients had significantly longer wait times to all treatments compared to non-Hispanic patients (first treatment 33.44 vs. 20.45 days, surgery 40.06 vs. 26.49 days, radiotherapy 114.68 vs. 96.42 days, chemotherapy 92.70 vs. 58.71 days). Uninsured patients, patients at academic facilities, and patients in metropolitan areas also had the longest wait times to treatment.
Conclusion: This study identified multiple disparities related to SES and demographics that correspond to delays in time to treatment. It is crucial that this topic is investigated further to help mitigate these incongruities in thyroid cancer care in the future.
(Copyright © 2023, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze: MEDLINE